{"name":"Oupushifang Pharmaceutical Technology Co., Ltd.","slug":"oupushifang-pharmaceutical-technology-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Atropine sulfate eye drops 0.01%","genericName":"Atropine sulfate eye drops 0.01%","slug":"atropine-sulfate-eye-drops-0-01","indication":"Myopia control in children","status":"phase_3"},{"name":"Atropine sulfate eye drops 0.02%","genericName":"Atropine sulfate eye drops 0.02%","slug":"atropine-sulfate-eye-drops-0-02","indication":"Myopia progression control in children (Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"Atropine sulfate eye drops 0.01%","genericName":"Atropine sulfate eye drops 0.01%","slug":"atropine-sulfate-eye-drops-0-01","phase":"phase_3","mechanism":"Atropine is a muscarinic acetylcholine receptor antagonist that blocks parasympathetic signaling in the eye to inhibit accommodation and pupil constriction.","indications":["Myopia control in children","Cycloplegia for refraction"],"catalyst":""},{"name":"Atropine sulfate eye drops 0.02%","genericName":"Atropine sulfate eye drops 0.02%","slug":"atropine-sulfate-eye-drops-0-02","phase":"phase_3","mechanism":"Atropine blocks muscarinic acetylcholine receptors in the eye to dilate the pupil and paralyze accommodation, slowing myopia progression in children.","indications":["Myopia progression control in children (Phase 3)"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}